As more gene and CAR-T therapies enter the market, especially in therapeutic categories with more patients such as cancer, experts say manufacturers will have to up their game in establishing the true value of their therapies, and work closely with payers on payment agreements. Precision for Value experts Jeremy Schafer and Alex Grosvenor offer their perspectives in this MedAd News cover story.

To read the full article, please click here.